Management of Overlapping Systemic Lupus Erythematosus and Sjögren’s Syndrome

Foundational Therapy

Hydroxychloroquine should be prescribed to every patient with SLE‑Sjӧgren’s overlap at a dose ≤5 mg/kg real body weight to balance efficacy with retinal safety – applicable regardless of disease activity or organ involvement and associated with reduced flares and damage accrual. 1

During maintenance, prednisone (or equivalent) should be kept < 7.5 mg/day, with attempts at complete withdrawal when feasible; higher doses markedly increase irreversible organ‑damage risk. 1
Short‑course glucocorticoids are acceptable for acute exacerbations; intravenous methylprednisolone pulses are reserved for severe disease. 2

Methotrexate, azathioprine, or mycophenolate should be initiated early to accelerate glucocorticoid tapering and sustain disease control; choice should be individualized based on comorbidities and safety, as no head‑to‑head superiority has been demonstrated. 1
These agents are normally combined with low‑dose glucocorticoids rather than used as monotherapy. 2

Aim for remission or low disease activity defined as SLEDAI ≤ 4, physician global assessment ≤ 1, and prednisone ≤ 7.5 mg/day. 3
For the Sjögren’s component, monitor the ESSDAI; a therapeutic response is a ≥3‑point reduction. 2
Flare risk is higher in younger patients, those not receiving antimalarials, and those with persistent serological activity. 3

Rituximab (1 g on day 0 and day 15) is recommended for severe, refractory systemic disease affecting either SLE or Sjögren’s; it carries the highest level of evidence among biologics in Sjögren’s (Level 1b) with efficacy demonstrated in >400 patients. Indications include vasculitis, cryoglobulinemia‑related complications, and MALT lymphoma. 2
Belimumab (10 mg/kg at weeks 0, 2, 4 then every 4 weeks) should be added for persistently active or flaring extrarenal SLE manifestations; in Sjögren’s, it achieved response in ~60 % of patients previously refractory to rituximab. 1

NSAIDs may be used for musculoskeletal pain but limited to 7–10 days. 2
Cyclophosphamide pulses (0.5 g every 15 days, up to six pulses) are an option for severe organ involvement. 2
Intravenous immunoglobulin (0.4–2 g/kg over 5 days) or plasma exchange can be considered for life‑threatening manifestations. 4

Screen for antiphospholipid antibodies in all overlap patients. 1
Assess cardiovascular risk and, when indicated, initiate low‑dose aspirin and lipid‑lowering therapy. 3
Vigilantly monitor infection risk, especially when immunosuppressive agents are used. 1

Do not postpone immunosuppressive therapy; early initiation facilitates glucocorticoid discontinuation and limits long‑term damage. 1
More than 95 % of patients receiving immunosuppressants for Sjögren’s also receive glucocorticoids, supporting a combination‑therapy approach. 2
Rituximab may be employed for organ‑threatening refractory SLE when conventional immunosuppressants fail. 1
Preventing disease flares is a core treatment milestone alongside achieving remission or low disease activity. 3
In patients requiring prolonged glucocorticoids, especially with severe organ impairment, adding immunosuppressive agents is justified as steroid‑sparing therapy. 2
Close, regular monitoring and optimization of disease control reduces flare risk in high‑risk individuals. 3

Aim to keep chronic prednisone (or equivalent) ≤ 7.5 mg/day to prevent irreversible organ damage in patients whose complement levels have normalized. 5
When feasible, discontinue glucocorticoids completely, because daily doses > 7.5 mg are associated with a markedly increased risk of cumulative damage. 5

Continue or start conventional immunosuppressants such as methotrexate, azathioprine, or mycophenolate to facilitate glucocorticoid tapering; do not reduce these agents solely because complements have normalized. 5
Maintain hydroxychloroquine at ≤ 5 mg/kg real body weight indefinitely, as it is recommended for all SLE patients regardless of current disease activity. 5
Preserve the current conventional immunomodulatory regimen that achieved complement normalization (e.g., methotrexate, azathioprine, or mycophenolate). 5

If complement normalization was attained while the patient was receiving a biologic agent (belimumab, rituximab, or anifrolumab), continue that biologic, because discontinuation carries a high risk of disease flare. 6

Strive for remission or a lupus low disease‑activity state (LLDAS), defined as SLEDAI ≤ 4, physician global assessment ≤ 1, and prednisone ≤ 7.5 mg/day; achieving these states reduces long‑term damage accrual (odds ratios 0.49–0.75 for remission, 0.19–0.88 for LLDAS). 6

In patients with a history of lupus nephritis, maintain maintenance immunosuppression (mycophenolate or azathioprine) even after complement normalization to prevent relapse. 6

Evaluate cardiovascular risk factors regularly and initiate preventive measures (e.g., low‑dose aspirin, lipid‑lowering therapy) when indicated. 5
Screen all patients for antiphospholipid antibodies, as complement normalization does not eliminate thrombotic risk in antibody‑positive individuals. 5